1.Post COVID-19 syndrome and new onset diseases: a prospective observational study.
Nitin SINHA ; Mahinder Pal Singh CHAWLA ; Desh DEEPAK ; Amit SURI ; Piyush JAIN ; Ankit AGARWAL ; Manoj Kumar BHAKHAR
Singapore medical journal 2025;66(7):354-361
INTRODUCTION:
The National Institute of Health and Care Excellence (NICE) has defined the terms, 'acute coronavirus disease 2019' (COVID-19), 'ongoing symptomatic COVID-19' and 'post-COVID-19 syndrome', with the latter two described as having persistent symptoms after the onset of COVID-19 symptoms for 4-12 weeks and >12 weeks, respectively. Persistent symptoms can either be due to the after-effects of COVID-19 or new-onset diseases after acute COVID-19. All symptoms observed beyond 4 weeks after the onset of COVID-19 need not be present at the time of onset. Previous studies on persistent post-COVID-19 symptoms have not mentioned new-onset diseases after acute COVID-19, and only a select few studies have discussed such new-onset symptoms.
METHODS:
Ninety-five patients who attended the post-COVID-19 clinic completed the requisite follow-up till 16 weeks after COVID-19 symptom onset. Data was recorded on a predesigned proforma. Necessary investigations were conducted to rule out any other cause of persistent symptoms.
RESULTS:
Fatigue (62.1%), breathlessness (50.5%) and cough (27.4%) were the most common symptoms present beyond 4 weeks after the onset of COVID-19 symptoms. Forty-nine (51.57%) patients developed post-COVID-19 syndrome - their severity of symptoms (odds ratio [OR] 17.77) and longer duration of hospital stay (OR 1.095) during acute disease were significantly associated with the development of post-COVID-19 syndrome. During follow-up, 25 patients developed new-onset symptoms, such as diabetes mellitus, hypertension and idiopathic tachycardia.
CONCLUSION
Patients can have persistent symptoms, new-onset symptoms and new-onset diseases after recovery from acute COVID-19.
Humans
;
COVID-19/diagnosis*
;
Female
;
Male
;
Prospective Studies
;
Middle Aged
;
Adult
;
Fatigue/etiology*
;
Post-Acute COVID-19 Syndrome
;
SARS-CoV-2
;
Aged
;
Cough/etiology*
;
Dyspnea/etiology*
2.Efficacy of Endovascular Glue Embolization in Treating Ruptured Intracranial Mycotic Aneurysms: A Single Center Experience
Sukalyan PURKAYASTHA ; Rajinder KUMAR ; Dinesh VERMA ; Deepak DHURVEY ; Nitin KUMAR ; Surajit JANA
Neurointervention 2024;19(3):156-161
Purpose:
Intracranial mycotic aneurysms (IMAs), rare and often life-threatening, result from arterial wall infections typically caused by bacteria such as Staphylococcus and Streptococcus. The standard treatment for ruptured aneurysms is not well-defined and often individualized. This study investigates the efficacy of endovascular glue embolization in managing ruptured IMAs, based on our center’s experience.
Materials and Methods:
A retrospective analysis was conducted for ruptured IMAs treated with glue embolization between January 2016 and December 2023. The procedure involved aneurysm sac and parent vessel occlusion with glue delivery. Data included patient demographics, clinical presentations, and neuroimaging. Clinical outcomes were assessed using the modified Rankin scale (mRS) at 3 months, and angiographic follow-up was conducted at 6 months.
Results:
The study included 28 patients, predominantly male (64.3%), with a mean age of 48 years. Headache was the primary symptom in 92.9% of cases, and positive blood/cerebro spinal fluid cultures were found in 82.14% of cases. All aneurysms were located in the distal circulation, primarily in the anterior circulation system. Glue embolization was successfully performed in all cases, achieving complete aneurysm sac and parent vessel obliteration. Follow-up at 3 months indicated mRS scores of 0 or 1 in 96.5% of cases. Six-month angiographic follow-up showed no aneurysm regrowth or new formations.
Conclusion
Endovascular glue embolization demonstrated high efficacy and safety in treating ruptured IMAs, with a 100% obliteration rate and favorable clinical outcomes in this single-center experience. Despite limitations such as its retrospective design and small sample size, the study supports glue embolization as a viable, less invasive alternative to traditional surgery. Further comparative studies are needed to confirm these findings and refine treatment approaches.
3.South Asian Working Action Group on SARCOpenia (SWAG-SARCO) e A consensus document
Minakshi DHAR ; Nitin KAPOOR ; Ketut SUASTIKA ; Mohammad E. KHAMSEH ; Shahjada SELIM ; Vijay KUMAR ; Syed Abbas RAZA ; Umal AZMAT ; Monika PATHANIA ; Yovan Parikshat Rai MAHADEB ; Sunny SINGHAL ; Mohammad Wali NASERI ; IGP Suka ARYANA ; Subarna Dhoj THAPA ; Jubbin JACOB ; Noel SOMASUNDARAM ; Ali LATHEEF ; Guru Prasad DHAKAL ; Sanjay KALRA
Osteoporosis and Sarcopenia 2022;8(2):35-57
The South Asian population is rapidly ageing and sarcopenia is likely to become a huge burden in this region if proper action is not taken in time. Several sarcopenia guidelines are available, from the western world and from East Asia. However, these guidelines are not fully relevant for the South Asian healthcare ecosystem. South Asia is ethnically, culturally, and phenotypically unique. Additionally, the region is seeing an increase in non-communicable lifestyle disease and obesity. Both these conditions can lead to sarcopenia. However, secondary sarcopenia and sarcopenic obesity are either not dealt with in detail or are missing in other guidelines. Hence, we present a consensus on the screening, diagnosis and management of sarcopenia, which addresses the gaps in the current guidelines. This South Asian consensus gives equal importance to muscle function, muscle strength, and muscle mass; provides cost-effective clinical and easy to implement solutions; highlights secondary sarcopenia and sarcopenic obesity; lists commonly used biomarkers; reminds us that osteo-arthro-muscular triad should be seen as a single entity to address sarcopenia; stresses on prevention over treatment; and prioritizes nonpharmacological over pharmacological management. As literature is scarce from this region, the authors call for more South Asian research guided interventions.
4.Mucoepidermoid carcinoma of the trachea in a 9-year-old male child: case report and review of literature
Deepak Kumar UPPAL ; Renu MADAN ; Nitin J. PETERS ; Amanjit BAL ; Nagarjun BALLARI ; Shikha GOYAL ; Divya KHOSLA
Radiation Oncology Journal 2022;40(3):208-212
Mucoepidermoid carcinoma (MEC) is most common malignancy of minor salivary glands in adults. Pulmonary MEC is extremely uncommon comprising of only 0.1%–0.2% of the primary lung malignancies and <1% of primary bronchial tumors. It is even rarer in children and literature limited to few case reports only. Here we present a case report of a 9-year-old boy diagnosed with primary MEC of trachea along with review of the literature. A 9-year-old male child presented with complaint of dry cough for two years which was later associated with shortness of breath after one year. Bronchoscopic examination revealed a growth arising from right lateral wall of carina occluding 50% of the lumen and detailed histopathological examination revealed it to be a MEC of the trachea. Patient underwent local excision of the tumor with primary anastomosis. In view of positive margins adjuvant radiotherapy of 60 Gy in 30 fractions were given to the tumor bed. Patient tolerated the treatment well and is disease free at 6 months follow-up. Experience with MEC of the trachea in children is limited and optimal treatment protocols have not been defined, with current treatment mainly extrapolated from MEC of the salivary glands.
7.Small interfering RNA for cancer treatment: overcoming hurdles in delivery.
Nitin Bharat CHARBE ; Nikhil D AMNERKAR ; B RAMESH ; Murtaza M TAMBUWALA ; Hamid A BAKSHI ; Alaa A A ALJABALI ; Saurabh C KHADSE ; Rajendran SATHEESHKUMAR ; Saurabh SATIJA ; Meenu METHA ; Dinesh Kumar CHELLAPPAN ; Garima SHRIVASTAVA ; Gaurav GUPTA ; Poonam NEGI ; Kamal DUA ; Flavia C ZACCONI
Acta Pharmaceutica Sinica B 2020;10(11):2075-2109
In many ways, cancer cells are different from healthy cells. A lot of tactical nano-based drug delivery systems are based on the difference between cancer and healthy cells. Currently, nanotechnology-based delivery systems are the most promising tool to deliver DNA-based products to cancer cells. This review aims to highlight the latest development in the lipids and polymeric nanocarrier for siRNA delivery to the cancer cells. It also provides the necessary information about siRNA development and its mechanism of action. Overall, this review gives us a clear picture of lipid and polymer-based drug delivery systems, which in the future could form the base to translate the basic siRNA biology into siRNA-based cancer therapies.
8.Effects of urea, metal ions and surfactants on the binding of baicalein with bovine serum albumin$
Dinda Kumar Amit ; Pandey Kumar Nitin ; Dasgupta Swagata
Journal of Pharmaceutical Analysis 2016;6(4):256-267
The interaction of baicalein with bovine serum albumin (BSA) was investigated with the help of spec-troscopic and molecular docking studies. The binding affinity of baicalein towards BSA was estimated to be in order of 105 M?1 from fluorescence quenching studies. NegativeΔH° (?5.6670.14 kJ/mol) and positive (ΔS°) ( t 79.96 7 0.65 J/mol K) indicate the presence of electrostatic interactions along with the hydrophobic forces that result in a positiveΔS°. The hydrophobic association of baicalein with BSA di-minishes in the presence of sodium dodecyl sulfate (SDS) due to probable hydrophobic association of baicalein with SDS, resulting in a negativeΔS° ( ? 40.65 7 0.87 J/mol K). Matrix-assisted laser desorption ionization/time of flight (MALDI–TOF) experiments indicate a 1:1 complexation between baicalein and BSA. The unfolding and refolding phenomena of BSA were investigated in the absence and presence of baicalein using steady-state and fluorescence lifetime measurements. It was observed that the presence of urea ruptured the non-covalent interaction between baicalein and BSA. The presence of metal ions (Ag t , Mg2 t , Ni2 t , Mn2 t , Co2 t and Zn2 t ) increased the binding affinity of ligand towards BSA. The changes in conformational aspects of BSA after ligand binding were also investigated using circular di-chroism (CD) and Fourier transform infrared (FT-IR) spectroscopic techniques. Site selectivity studies following molecular docking analyses indicated the binding of baicalein to site 1 (subdomain IIA) of BSA.&2016 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article.
9.Right sided double inferior vena cava with obstructed retrocaval ureter: Managed with single incision multiple port laparoscopic technique using "Santosh Postgraduate Institute tacking ureteric fixation technique".
Santosh KUMAR ; Shivanshu SINGH ; Nitin GARG
Korean Journal of Urology 2015;56(4):330-333
Right double inferior vena cava with obstructed retrocaval ureter is an extremely rare anomaly with only a few reported cases in the literature. To the best of our knowledge, this is the first case report describing ureteric repair by use of a single-incision laparoscopic technique. In addition, this report addresses the underlying surgical challenges of this repair and provides a brief review of the embryology of this anomaly. The "Santosh Postgraduate Institute ureteric tacking fixation technique" provides ease of end-to-end uretero-ureteric anastomosis in a single-incision laparoscopic surgery.
Humans
;
Intraoperative Care/methods
;
Intraoperative Complications/*prevention & control
;
Laparoscopy/methods
;
Magnetic Resonance Imaging
;
Male
;
*Retrocaval Ureter/diagnosis/physiopathology/surgery
;
Treatment Outcome
;
Urography/methods
;
Urologic Surgical Procedures/*methods
;
*Vena Cava, Inferior/abnormalities/surgery
;
Young Adult
10.siMacro: A Fast and Easy Data Processing Tool for Cell-Based Genomewide siRNA Screens.
Nitin Kumar SINGH ; Bo Yeun SEO ; Mathukumalli VIDYASAGAR ; Michael A WHITE ; Hyun Seok KIM
Genomics & Informatics 2013;11(1):55-57
Growing numbers of studies employ cell line-based systematic short interfering RNA (siRNA) screens to study gene functions and to identify drug targets. As multiple sources of variations that are unique to siRNA screens exist, there is a growing demand for a computational tool that generates normalized values and standardized scores. However, only a few tools have been available so far with limited usability. Here, we present siMacro, a fast and easy-to-use Microsoft Office Excel-based tool with a graphic user interface, designed to process single-condition or two-condition synthetic screen datasets. siMacro normalizes position and batch effects, censors outlier samples, and calculates Z-scores and robust Z-scores, with a spreadsheet output of >120,000 samples in under 1 minute.
High-Throughput Screening Assays
;
RNA Interference
;
RNA, Small Interfering

Result Analysis
Print
Save
E-mail